title: Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience.
abstract: OBJECTIVE
  To evaluate, in three Spanish tertiary referral centres, the short-term safety and efficacy of golimumab (GLM) for treatment of immune-mediated uveitis resistant to previous immunosuppressive therapy.
  
  
  METHODS
  Nonrandomized retrospective interventional case series. Thirteen patients with different types of uveitis that were resistant to treatment with at least 2 previous immunosuppressors were included in this study. All included patients were treated with GLM (50 mg every four weeks) during at least 6 months. Clinical evaluation and treatment-related side effects were assessed at least four times in all included patients.
  
  
  RESULTS
  Eight men and 5 women (22 affected eyes) with a median age of 30 years (range 20-38) and active immune-mediated uveitides were studied. GLM was used in combination with conventional immunosuppressors in 7 patients (53.8%). GLM therapy achieved complete control of inflammation in 12/13 patients (92.3%) after six months of treatment. There was a statistically significant improvement in mean BCVA (0.60 versus 0.68, P = 0.009) and mean 1 mm central retinal thickness (317 versus 261.2 μ, P = 0.05) at the six-month endpoint when compared to basal values. No major systemic adverse effects associated with GLM therapy were observed.
  
  
  CONCLUSIONS
  GLM is a new and promising therapeutic option for patients with severe and refractory uveitis.
authors: Department of Ophthalmology, University Hospital of León, 24071 León, Spain ; Uveitis Unit, University Hospital of León, 24071 León, Spain ; Institute of Biomedicine (INBIOMED), University of León, León, Spain.
authors: Miguel
authors: M
authors: Cordero-Coma
authors: Department of Rheumatology, University Hospital "Marques de Valdecilla", IFIMAV, 39008 Santander, Spain.
authors: Vanesa
authors: V
authors: Calvo-Río
authors: Department of Ophthalmology, University Hospital "Clínic", 08036 Barcelona, Spain.
authors: Alfredo
authors: A
authors: Adán
authors: Department of Rheumatology, University Hospital "Marques de Valdecilla", IFIMAV, 39008 Santander, Spain.
authors: Ricardo
authors: R
authors: Blanco
authors: Department of Rheumatology, University Hospital of León, 24071 León, Spain.
authors: Carolina
authors: C
authors: Álvarez-Castro
authors: Department of Ophthalmology, University Hospital "Clínic", 08036 Barcelona, Spain.
authors: Marina
authors: M
authors: Mesquida
authors: Uveitis Unit, University Hospital of León, 24071 León, Spain ; Department of Immunology, University Hospital of León, 24071 León, Spain.
authors: Sara
authors: S
authors: Calleja
authors: Department of Rheumatology, University Hospital "Marques de Valdecilla", IFIMAV, 39008 Santander, Spain.
authors: Miguel A
authors: MA
authors: González-Gay
authors: Uveitis Unit, University Hospital of León, 24071 León, Spain ; Institute of Biomedicine (INBIOMED), University of León, León, Spain ; Department of Immunology, University Hospital of León, 24071 León, Spain.
authors: José G
authors: JG
authors: Ruíz de Morales
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D012189:Retrospective Studies; D016896:Treatment Outcome; D014605:Uveitis / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; C529000:golimumab